Clarithromycin against Mycobacterium avium complex infections

Tubercle and Lung Disease

Volumn 77, Issue 1, 1996, Pages 19-26

  Heifets, L B ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; ALBUMIN; AMIKACIN; AZITHROMYCIN; CATALASE; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; GLUCOSE; MACROLIDE; OLEIC ACID; RIFABUTIN; RIFAMPICIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL GENE; BACTERIUM MUTANT; CROSS RESISTANCE; DRUG EFFICACY; GENE MUTATION; HUMAN; LUNG DISEASE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; RELAPSE; REVIEW; SIDE EFFECT;

EID: 0030063594     PISSN: 09628479     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0962-8479(96)90070-2     Document Type: Review

References (105)

1. H Gruft D Blanchard J Wheeler Ocean waters a source of Mycobacterium intracellulare Am Rev Respir Dis 113 1976 60 (no. 4, part 2)
2. M Tsukamura N Kita H Shimoide H Arakawa A Kuze Studies on the epidemiology of nontuberculous mycobacteriosis in Japan Am Rev Respir Dis 137 1988 1280 1284
3. M Tsukamura H Shimoide N Kita Epidemiologic studies of lung disease due to mycobacteria other than Mycobacterium tuberculosis in Japan Rev Infect Dis 3 1981 997 1007
4. E Wolinsky Nontuberculosis mycobacteria and associated diseases Am Rev Respir Dis 119 1979 107 159
5. RC Good DE Snider Jr Isolation of nontuberculous mycobacteria in the United States, 1980 J Infect Dis 146 1982 829
6. GL Woods JA Washington Mycobacteria other than M. tuberculosis : a review of microbiologic and clinical aspects Rev Inf Dis 9 1987 275 294
7. MD Iseman RF Corpe RJ O'Brien DY Rosenzweig E Wolinsky Disease due to Mycobacterium aviumintracellulare Chest 87 1985 139S 145S
8. RE Chaisson RD Moore DD Richman J Keruly T Creagh Incidence and natural history of Mycobacterium avium -complex infections in patients with advanced HIV disease treated with zidovudine The Zidovudine Epidemiology Study Group 2nd edition Am Rev Respir Dis 146 1992 285 289
9. DR Hoover AJ Saah H Bacellar J Phair RRA Detels Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis N Engl J Med 329 1993 1922 1926
10. CR Horsburgh Jr Current concepts: Mycobacterium ovium complex infection in the acquired immunodeficiency syndrome N Engl J Med 324 1991 1332
11. CR Horsburgh Jr RM Selik The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS) Am Rev Respir Dis 139 1989 4 7
12. SD Nightingale LT Byrd PM Southern JD Jockusch SX Cal BA Wynne Incidence of Mycobacterium aviumintracellulare complex bacteremia in human immunodeficiency virus-positive patients J Infect Dis 165 1992 1082 1085
13. JO Falkinham III BC Parker H Gruft Epidemiology of infection by nontuberculous mycobacteria Am Rev Respir Dis 121 1980 931 937
14. BC Parker MA Ford H Gruft JO Falkinham Epidemiology of infection by nontuberculous mycobacteria. IV. Preferential aerosolization of M. intracellulare from natural waters Am Rev Respir Dis 128 1983 652 656
15. SG Wendt KL George BC Parker H Croft JO Falkinham Epidemiology of infection by nontuberculous mycobacteria. III. Isolation of potentially pathogenic mycobacteria from aerosols Am Rev Respir Dis 112 1980 259 263
16. Heifets L, Iseman M D. Personal communication. 1993.
17. H Tomioka K Sato H Saito In vitro susceptibilities of M. ovium and M. intracellulare to various drugs Kekkaku 66 1991 13 16
18. LS Guthertz B Damsker B EJ EG Ford TF Midura JM Janda M. avium and M. intracellulare infections in patients with and without AIDS J Infect Dis 160 1989 1037 1041
19. MA Yakrus RC Good Geographic distribution, frequency, and specimen source of M. avium serotypes isolated from patients with acquired immunodeficiency syndrome J Clin Microbiol 28 1990 926 931
20. JH Bates A study of pulmonary disease associated with mycobacteria other than Mycobacterium tuberculosis : clinical characteristics: XX. A report of the Veterans Administration - Armed Forces cooperative study on the chemotherapy of tuberculosis Am Rev Respir Dis 96 1967 1151 1157
21. RF Corpe Clinical aspects, medical and surgical, in the management of Battey-type pulmonary disease Chest 35 1964 380 382
22. PT Davidson V Kanijo M Goble TS Moulding Treatment of disease due to Mycobacterium intracellulare Rev Infect Dis 3 1981 1052 1053
23. W Lester DA Fischer TS Moulding RI Fraser JK McClatchy Evaluation of chemotherapy responses in group III (Battey-type) mycobacterial infections Transaction of the 27th Veterans Administration - Armed Forces Pulmonary Disease Research Conference 1968 20
24. W Lester T Moulding RI Fraser JK McClatchy Quintuple drug regimens in the treatment of Battey-type infections Transactions of the 28th Veterans Administration - Armed Forces Pulmonary Disease Research Conference 1969 83
25. JK Seydel KJ Schaper S Rüsch-Gerdes Development of effective drug combinations for the inhibition of multiply resistant mycobacteria, especially of the Mycobacterium avium complex Chemotherapy 38 1992 159 168
26. P Hopewell M Cynamon J Starke M Iseman R O'Brien Evaluation of new anti-infective drugs for the treatment and prevention of infections caused by the Mycobacterium avium complex Clin Inf Dis 15 Suppl. 1 1992 S296 S306
27. JJ Ellner MJ Goldberger PM Parenti Mycobacterium avium infection in AIDS: a therapeutic dilemma in rapid evolution J Inf Dis 163 1993 1326 1335
28. LB Heifets Dilemmas and realities in drug susceptibility testing of M. avium-M. intracellulare and other slowly growing nontuberculous mycobacteria LB Heifets Drug susceptibility in the chemotherapy of mycobacterial infections 1991 CRC Press Boca Raton, FL 123 146
29. LB Heifets MD Iseman Choice of antimicrobial agents for M. avium disease based on quantitative tests of drug susceptibility N Engl J Med 323 1990 419 420
30. CB Inderlied CA Kemper LEM Bermudez The Mycobacterium avium complex Clin Microbiol Rev 6 1993 266 310
31. RJ Wallace Jr BA Brown E Griffith Initial clarithromycin monotherapy for Mycobacterium aviumintracellulare complex lung disease Am J Respir Crit Care Med 149 1994 1335 1341
32. JL Ferrero BA Bopp KC Marsh Metabolism and disposition of clarithromycin in man Drug Metabol Dispos 18 1990 441 446
33. RG Finch DCE Speller PJ Daly Clarithromycin: new approaches to the treatment of respiratory tract infections J Antimicrob Chemother 27 Suppl. A 1991 1 124
34. LB Baradell GL Plosker D McTavish Clarithromycin A review of its pharmacological properties and therapeutic use in Mycobacterium avium-intracellulare complex infection in patients with Acquired Immune Deficiency Syndrome 2nd edition Drugs 46 1993 289 312 (2)
35. SC Piscitelli LH Danziger KA Rodvold Clarithromycin and azithromycin: new macrolide antibiotics Clin Pharm 11 1992 137 152
36. MG Surgill RP Rapp Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and andverse effects profiles Ann Pharm 26 1992 1099 1108
37. HA Kirst GD Sides New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy Antimicrob, Agents Chemother 33 1989 1419 1422
38. S Chu Y Park C Locke DS Wilson JC Cavanaugh Drug-food interaction potential of clarithromycin, a new macrolide antibiotic J Clin Pharmacol 32 1992 32 36
39. I Nakayama Macrolides in clinical practice S Omura Macrolide antibiotics: chemistry, biology and practice 1984 Academic Press Inc Orlando, FL 261 300
40. B Dautzenberg C Truffot S Legris Clarithromycin against Mycobacterium avium infection in AIDS patients: a controlled clinical trial Am Rev Respir Dis 144 1991 564 569
41. B Ruf D Schürmann H Mauch G Jautzke FJ Fehrenbach HD Pohle Effectiveness of the macrolide clarithromycin in the treatment of Mycobacterium avium complex infection in HIVinfected patients Infection 20 1992 267 272
42. B Dautzenberg T Saint Marc MC Meyohas Clarithromycin and other antimycobacterial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome Arch Intern Med 153 1993 368 373
43. B Dautzenberg Clinical trials in M. avium therapy: lessons to take home Res Microbiol 145 1994 197 206
44. RE Chaisson CA Benson MP Dube Clarithromycin therapy for bacteremic Mycobacterium avium complex disease A randomized, double-blind, dose-ranging study in patients with AIDS 2nd edition Ann Intern Med 121 1994 905 911
45. LS Young L Wiviott M Wu P Kolonoski R Bolan CB Inderlied Azithromycin for treatment of Mycobacterium aviumintracellulare complex infection in patients with AIDS Lancet 338 1991 1107 1109
46. H Masur Public Health Service Task Force on Prophylaxis and Therapy for M.avium complex US Recommendations on prophylaxis and therapy for disseminated M. avium complex disease in patients infected with the HIV (Special Report) N Engl J Med 329 1993 898 904
47. L Heifets N Mor J Vanderkolk M. avium strains resistant to clarithromycin and azithromycin Antimicrob Agents Chemother 37 1993 2364 2370
48. Telenti A. Personal communication. 1994.
49. Mazurek G H. Personal communication. 1993.
50. A Meier P Kirschner B Springer Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare Antimicrob Agents Chemother 38 1994 381 384
51. A Meier RJ Wallace P Sander L Heifets EC Böttger Molecular mechanisms of resistance to clarithromycin in mycobacteria 95 ASM General Meeting 2nd edition Abstract U-41 1995 124
52. H Tomioka K Sato H Saito In vitro antimycobacterial activity of clarithromycin and its therapeutic efficacy against Mycobacterium intracellulare infection induced in mice Kekkaku 68 1993 11 17
53. AL Barry RN Jones C Thornsberry In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin Antimicrob Agents Chemother 32 1988 752 754
54. N Bahal M Nahata The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin Ann Pharmacother 25 1992 46 55
55. BA Brown RJ Wallace Jr G Onyi Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system Antimicrob Agents Chemother 36 1992 1987 1990
56. PB Fernandes DJ Hardy D McDaniel CW Hanson RN Swanson In vitro and in vivo activities of clarithromycin against Mycobacterium avium Antimicrob Agents Chemother 33 1989 1531 1534
57. EA Gorzynski SI Gutman W Allen Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin Antimicrob Agents Chemother 33 1989 591 592
58. LB Heifets PJ Lindholm-Levy RD Comstock Clarithromycin minimal inhibitory and bactericidal concentrations Am Rev Respir Dis 145 1992 856 858
59. RJ Kent M Bakhtiar DC Shanson The in vitro bactericidal activities of combinations of antimicrobial agents against clinical isolates of Mycobacterium avium-intracellulare J Antimicrob Chemother 30 1992 643 650
60. N Khardori K Rolston B Rosenbaum S Hayat GP Bodey Comparative in vitro activity of 20 antimicrobial agents against clinical isolates of Mycobacterium avium complex J Antimicrob Chemother 24 1989 667 673
61. S Naik R Ruck In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex Antimicrob Agents Chemother 33 1989 1614 1616
62. N Rastogi KS Goh Effect of pH on radiometric MICs of clarithromycin against 18 species of mycobacteria Antimicrob Agents Chemother 36 1992 2841 2842
63. C Truffot-Pernot B Ji J Grosset Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex Antimicrob Agents Chemother 35 1991 1677 1678
64. SL Hansen P Swomley G Drusano Effect of carbon dioxide and pH on susceptibility of Bacteroides fragilis group to erythromycin Antimicrob Agents Chemother 19 1981 335 336
65. V Lorian LD Sabath Effect of pH on the activity of erythromycin against 500 isolates of gram-negative bacilli Appl Microbiol 20 1970 754 756
66. National Committee for Clinical Laboratory Standards Performance standards for antimicrobial susceptibility testing 2nd edition JH Jorgensen National Committee for Clinical Laboratory Standards, M100-S4 ed, Villanova 1992
67. R Anderson G Joone CEJ van Rensburg An in vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent J Antimicrob Chemother 22 1988 922 923
68. M Ishiguro H Koga S Kohno T Hayashi K Yamaguchi M Hirota Penetration of macrolides into human polymolphonuclear leukocytes J Antimicrob Chemother 24 1989 719 729
69. Y Kohno H Yoshida T Suwa T Suga Uptake of clarithromycin by rat lung cells J Antimicrob Chemother 26 1990 503 513
70. N Mor J Vanderkolk L Heifets Accumulation of clarithromycin in macrophages infected with M. avium Pharmacotherapy 14 I 1994 100 104 (I)
71. N Mor L Heifers MIC and MBC of clarithromycin against Mycobacterium avium within human macrophages Antimicrob Agents Chemother 37 1993 111 114
72. C dechastellier C Frehel C Offredo E Skamene Implication of phagosome-lysosome fusion in restriction of M. avium growth in bone marrow macrophages from genetically resistant mice Inf Immun 61 1993 3775 3784
73. C Perrone A Gikas C Truffot-Pernot J Grosset JJ Pocidalo JL Vilde Activities of clarithromycin sulfisoxale, and rifabutin against Mycobacterium avium complex multiplication within human macrophages Antimicrob Agents Chemother 1990 1508 1511
74. C Perrone A Gikas C Truffot-Pernot J Grosset JL Vilde JJ Pocidalo Activities of sparfloxacin, azithromycin, temafloxacin and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages Antimicrob Agents Chemother 35 1991 1356 1359
75. N Rastogi V Labrousse Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex Antimocrob Agents Chemother 35 1991 462 470
76. DM Yajko PT Nassos CA Sanders PC Gonzalez WK Hadley Comparison of the intracellular activities of clarlithromycin and erythromycin against M. avium complex strains in J774 cells in alveolar macrophages from human immunodeficiency virus 1-infected individuals Antimicrob Agents Chemother 36 1992 1163 1165
77. N Mor J Vanderkolk N Mezo L Heifets Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of M. avium Antimicrob Agents Chemother 38 1994 2738 2742
78. N Mor L Heifets Inhibition of intracellular growth of M. avium by one pulsed exposure of infected macrophages to clarithromycin Antimicrob Agents Chemother 37 1993 1380 1382
79. Y Cohen C Perrone C Truffot-Pernot J Grosset JL Vilde Activities of Win-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium Antimicrob Agents Chemother 36 1992 2104 2107
80. B Ji N Lounis C Truffot-Pernot J Grosset Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model Antimicrob Agents Chemother 38 1994 2521 2529
81. SP Klemens MS Destefano MH Cynamon Activity of clarithromycin against Mycobacterium avium complex infection in beige mice Antimicrob Agents Chemother 36 1992 2413 2417
82. B Ji N Lounis C Truffot-Pemot J Grosset Selection of resistant mutants of Mycobacterium avium in beige mice by clarithromycin monotherapy Antimicrob Agents Chemother 36 1992 2839 2840
83. GP Youmans EH Williston W Feldman CH Hinshaw Increase in resistance of tubercle bacilli to streptomycin A preliminary report 2nd edition Proc Mayo Clinic 21 1946 126 219
84. DA Mitchison Development of streptomycin resistant strains of tubercle bacilli in pulmonary tuberculosis Thorax 4 1950 144 155
85. Medical Research Council The treatment of pulmonary tuberculosis with isoniazid Br Med J 2 1952 735 746
86. SH Forbee A Theodore FW Mount Long-term consequences of isoniazid alone as initial therapy: US PHS Tuberculosis Therapy Trials Amer Rev Respir Dis 82 1960 824 830
87. LB Heifets Quantitative cultures and drug susceptibility testing of M. avium clinical isolates before and during the antimicrobial therapy Res Microbiol 145 1994 188 196
88. LB Heifets PJ Lindholm-Levy RD Comstock Bacteriostatic and bactericidal activities of geotamicin alone and in combination with clarithromycin against Mycobacterium avium Antimicrob Agents Chemother 36 1992 1695 1698
89. B Ji N Lounis C Truffot-Pernot JH Grosset In vitro activities of clarithromycin-containing double- or triple-drug combinations against Mycobacterium avium complex Program Abstract, First International Conference on Macrolides, Azalides and Streptomycins, vol January, Santa Fe 1992 Abstract 118
90. J Chiu J Nussbaum S Bozzette JG Tilles LS Young J Leedom Treatment of disseminated Mycobacterium avium complex infection with amikacin, ethambutol, rifampin, and ciprofloxacin Ann Intern Med 113 1990 358 361
91. MH Cynamon CE Swenson GS Palmer RS Ginsberg Liposome-encapsulated amikacin therapy of M. avium complex infection in beige mice Antimicrob Agents Chemother 33 1989 1179 1183
92. PRJ Gangadharam VK Perumal NR Podapati L Kesavalu MD Iseman In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infection in beige mice Antimicrob Agents Chemother 32 1988 1400 1403
93. CB Inderlied PT Kolonoski M Wu LS Young Amikacin, ciprofloxacin, and imipenem treatment for disseminated Mycobacterium avium complex infection in beige mice Antimicrob Agents Chemother 33 1989 176 180
94. H Saito K Saito Activity of rifabutin alone and in combination with clofazimine, kanamycin and ethambutol against Mycobacterium intracellulare infections in mice Tubercle 70 1989 201 205
95. BD Agins DS Berman D Spicehandler W El Sadr MS Simberkoff JJ Rahal Effect of combined therapy with ansamycin, clofazimine, ethambutol and isoniazid for Mycobacterium avium infection in patients with AIDS J Infect Dis 159 1989 734 737
96. JE Baron LS Young Amikacin, ethambutol, and rifampin for treatment of disseminated M. avium-intracellulare infection in patients with acquired immune deficiency syndrome Diagn Microbiol Infect Dis 5 1986 215 220
97. F De Lalla R Maserati P Scarpellini Clarithromycinciprofloxacin-amikacin for therapy of Mycobacterium avium Mycobacterium intracellulare bacteremia in patients with AIDS Antimicrob Agents Chemother 36 1992 1567 1569
98. CA Benson HA Kessler JC Pottage Jr GM Trenholme Successful treatment of acquired immunodeficiency syndrome-related Mycobacterium avium complex disease with a multiple drug regimen including amikacin Arch Intern Med 151 1991 582 585
99. T Lazard C Perronne J Grosset J-L Vilde J-J Pocidalo Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with M. avium Antimicrob Agents Chemother 37 1993 1690 1692
100. CA Kemper D Havlir D Haghighat M Dube AE Bartok JP Sison The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol and rifampin on Mycobacterium avium complex bacteremia in patients with AIDS J Infect Dis 170 1994 157 164
101. J Hoy A Mijch M Sandlum L Grayson R Lucas B Dwyer Quadruple-drug therapy for Mycobacterium avium intracellulare bacteremia in AIDS patients J Infect Dis 161 1990 801 805
102. CC Hawkins JW Gold E Whimbey Mycobacterium avium complex infections in patients with acquired immunodeficiency syndrome Ann Intern Med 105 1986 184 199
103. H Masur C Tuazon V Gill Effect of combined clofazimine and ansamycin therapy of Mycobacterium avium Mycobacterium intracellulare bacteremia in patients with AIDS J Infect Dis 155 1987 127 129
104. B Wong FF Edwards TE Kiehn Continuous high grade Mycobacterium avium intracellare bacteremia in patients with the acquired immune deficiency syndrome Am J Med 78 1985 35 40
105. CA Kemper TC Meng J Nussbaum J Chiu DF Fiegal AE Bartok Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug regimen: rifampin, ethambutol, clofazimine, and ciprofloxacin Ann Intern Med 116 1992 466 472